

VIVALIS ISSUES ITS FINANCIAL CALENDAR 2008

Nantes (France) – January 8th, 2008

The financial calendar for 2008 has been determined as follows:

Feb 14 th	Year 2007 Revenues
March 31 st	Annual accounts
May 14 th	Quarterly report Q1 2008
June 11 th -2 pm	Annual General Meeting
Aug. 13 th	Revenues Q2 2008
Aug. 29 th	Half-year report – June 2008
Nov. 13 th	Quarterly report Q3 2008

Financial data and information about VIVALIS are available on **the Company new web site:**
www.vivalis.com

About VIVALIS

VIVALIS (NYSE- Euronext: VLS) is a public biopharmaceutical company that provides innovative cell-based solutions for the industrial manufacture of viral vaccines and therapeutic proteins, and develops vaccines and drugs to prevent and treat viral diseases. VIVALIS' know-how and proprietary technologies are commercially exploited in three main areas:

- Vaccine development and manufacturing. VIVALIS grants research & commercial licences to its proprietary **EBx[®]** embryonic stem cell lines to pharmaceutical and biotechnology companies active in the viral vaccine business.
- Recombinant therapeutic protein and monoclonal antibody production systems development. VIVALIS partners with pharmaceutical and biotechnology companies in this area, to which it licences its proprietary **EBx[®]** embryonic stem cell lines to manufacture recombinant therapeutic proteins.
- The build-up of a proprietary portfolio of vaccines and anti-viral molecules.

Based in Nantes (France), VIVALIS was created in 1999 by Group GRIMAUD (1350 employees), the n°2 group worldwide in avian genetic breeding. Vivalis has established several partnerships with companies that are worldwide leaders in their respective fields, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Meril and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES cluster.

Eurolist Paris – Sector B – FR0004056851

Reuters: **VLS.PA** – Bloomberg: **VLS FP**

Investors Relation :

VIVALIS

NewCap

Franck Grimaud, C.E.O
Email : investors@vivalis.com

Financial Communication Agency
Steve Grobet / Emmanuel Huynh
Tel. : +33 (0) 1 44 71 94 91
Email : vivalis@newcap.fr